tetano
Editor, Senior Moderator
J Vaccines Vaccin. 2015 Jun;6(3). pii: 287. Epub 2015 Jun 30.
[h=1]Recombinant Hemagglutinin and Virus-Like Particle Vaccines for H7N9 Influenza Virus.[/h] Li X[SUP]1[/SUP], Pushko P[SUP]2[/SUP], Tretyakova I[SUP]2[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Cases of H7N9 human infection were caused by a novel, avian-origin H7N9 influenza A virus that emerged in eastern China in 2013. Clusters of human disease were identified in many cities in China, with mortality rates approaching 30%. Pandemic concerns were raised, as historically, influenza pandemics were caused by introduction of novel influenza A viruses into immunologically na?ve human population. Currently, there are no approved human vaccines for H7N9 viruses. Recombinant protein vaccine approaches have advantages in safety and manufacturing. In this review, we focused on evaluation of the expression of recombinant hemagglutinin (rHA) proteins as candidate vaccines for H7N9 influenza, with the emphasis on the role of oligomeric and particulate structures in immunogenicity and protection. Challenges in preparation of broadly protective influenza vaccines are discussed, and examples of broadly protective vaccines are presented including rHA stem epitope vaccines, as well as recently introduced experimental multi-HA VLP vaccines.
PMID: 26523241 [PubMed]
[h=1]Recombinant Hemagglutinin and Virus-Like Particle Vaccines for H7N9 Influenza Virus.[/h] Li X[SUP]1[/SUP], Pushko P[SUP]2[/SUP], Tretyakova I[SUP]2[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Cases of H7N9 human infection were caused by a novel, avian-origin H7N9 influenza A virus that emerged in eastern China in 2013. Clusters of human disease were identified in many cities in China, with mortality rates approaching 30%. Pandemic concerns were raised, as historically, influenza pandemics were caused by introduction of novel influenza A viruses into immunologically na?ve human population. Currently, there are no approved human vaccines for H7N9 viruses. Recombinant protein vaccine approaches have advantages in safety and manufacturing. In this review, we focused on evaluation of the expression of recombinant hemagglutinin (rHA) proteins as candidate vaccines for H7N9 influenza, with the emphasis on the role of oligomeric and particulate structures in immunogenicity and protection. Challenges in preparation of broadly protective influenza vaccines are discussed, and examples of broadly protective vaccines are presented including rHA stem epitope vaccines, as well as recently introduced experimental multi-HA VLP vaccines.
PMID: 26523241 [PubMed]